Company / Cash & Equivalents
Royalty Pharma plc Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$618.7M
FY2025
5-year range
$477.0M / $1.7B
FY2021-FY2025
Trend
-33.4%
vs FY2024
Sector context
#33 of 207
Health Care
What the data says
Royalty Pharma plc's cash & equivalents of $619M is higher than 84% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 7 years, ranging from $246M in FY2019 to $1.7B in FY2022.
Based on SEC 10-K filings.
$619M in FY2025 with a 5-year CAGR of -9.3%. Top quartile in the Health Care sector.
Improved from $477M to $619M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -28.8%
- 5-Year CAGR
- -9.3%
- 10-Year CAGR
- -
Sector benchmark
-7.6% below sector average
Key checks
Key Insights
- 5-year CAGR of -9.3%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 33.4% year-over-year.
- Ranks #33 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.91 (distress zone, below 1.8 threshold)
- Strong profit margin: 38.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $618.7M | -33.4% |
| FY2024 | $929.0M | +94.8% |
| FY2023 | $477.0M | -72.1% |
| FY2022 | $1.7B | +11.0% |
| FY2021 | $1.5B | +52.8% |
| FY2020 | $1.0B | +309.7% |
| FY2019 | $246.2M | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026